CoChat
Sign Up
Cited by 13

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN

Schnöder, Tina M., Eberhardt, Judith, Koehler, Michael, Bierhoff, Holger B., Weinert, Sönke, Pandey, Akhilesh Datt, Nimmagadda, Subbaiah Chary, Wolleschak, Denise, Jöhrens, Korinna, Fischer, Thomas, Heidel, Florian H.·2017·Journal of Cancer Research and Clinical Oncology
DOI 10.1007/s00432-017-2354-1
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00432-017-2354-1

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Alvarez-Larran A et al (2016) Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 101(8):926–931 · DOI
  2. Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122(13):2176–2184 · DOI
  3. Barbui T et al (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124(19):3021–3023 · DOI
  4. Baxter EJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061 · DOI · Paper page
  5. Bierhoff H et al (2014) Quiescence-induced LncRNAs trigger H4K20 trimethylation and transcriptional silencing. Mol Cell 54(4):675–682 · DOI · Paper page
  6. Blank T et al (2016) Brain endothelial- and epithelial-specific interferon receptor chain 1 drives virus-induced sickness behavior and cognitive impairment. Immunity 44(4):901–912 · DOI
  7. Borgland SL et al (2000) Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J Virol 74(9):3941–3947 · DOI
  8. Cervantes F et al (1997) Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 97(3):635–640 · DOI
  9. Cohen J (1988) Statistical power analysis for the behavioral sciences, Edn 2. Lawrence Erlbaum, Hillsdale
  10. Deininger M et al (2015) The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 126(13):1551–1554 · DOI · Paper page
  11. Finazzi G, Barbui T (2008) Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22(8):1494–1502 · DOI
  12. Finazzi G et al (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105(7):2664–2670 · DOI
  13. Fung FY et al (2013) Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia. Leuk Res 37(3):274–279 · DOI
  14. Geyer HL et al (2015) Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm 2015:284706 · DOI
  15. Harrison C et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798 · DOI · Paper page
  16. Hasselbalch HC (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119(14):3219–3225 · DOI · Paper page
  17. Heidel FH et al (2012) Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10(4):412–424 · DOI
  18. Heidel FH et al (2013) The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med 210(1):15–22 · DOI
  19. Hermouet S, Bigot-Corbel E, Gardie B (2015) Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediators Inflamm 2015:145293 · DOI
  20. Hinz A et al (2011) Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 33(5):462–468 · DOI
  21. Hoyo-Becerra C et al (2015) Rapid regulation of depression-associated genes in a new mouse model mimicking interferon-alpha-related depression in hepatitis C virus infection. Mol Neurobiol 52(1):318–329 · DOI
  22. James C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148 · DOI
  23. Kleppe M et al (2015) JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 5(3):316–331 · DOI
  24. Koehler M, Fischer T (2015) How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making. J Clin Oncol 33(9):1090–1091 · DOI
  25. Kralovics R et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790 · DOI · Paper page
  26. Lawrence T (2009) The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1(6):a001651 · DOI
  27. Lawrence T et al (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7(12):1291–1297 · DOI
  28. Levine RL et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397 · DOI · Paper page
  29. Marchioli R et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22–33 · DOI
  30. Mesa RA et al (2013) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 31(10):1285–1292 · DOI
  31. Mullally A et al (2010) Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17(6):584–596 · DOI
  32. Ostuzzi G et al (2015) Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev, 2015(6):CD011006
  33. Pardanani AD et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108(10):3472–3476 · DOI
  34. Pardanani A et al (2012) IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia 26(4):693–699 · DOI
  35. Passamonti F et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708 · DOI
  36. Pikman Y et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3(7):e270 · DOI
  37. Rampal R et al (2014) Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123(22):e123–e133 · DOI
  38. Scheidereit C (2006) IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25(51):6685–6705 · DOI
  39. Schnoder TM et al (2015) Epo-induced erythroid maturation is dependent on Plcgamma1 signaling. Cell Death Differ 22(6):974–985 · DOI
  40. Scott LM et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356(5):459–468 · DOI
  41. Seyidova-Khoshknabi D, Davis MP, Walsh D (2011) Review article: a systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care 28(2):119–129 · DOI
  42. Smets EM et al (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39(3):315–325 · DOI
  43. Tefferi A (2013) Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88(2):141–150 · DOI
  44. Tefferi A et al (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29(10):1356–1363 · DOI
  45. Tefferi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874–1881 · DOI
  46. Thekkumpurath P et al (2011) Screening for major depression in cancer outpatients: the diagnostic accuracy of the 9-item patient health questionnaire. Cancer 117(1):218–227 · DOI
  47. Vannucchi AM et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426–435 · DOI · Paper page
  48. Verstovsek S et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807 · DOI · Paper page
  49. Vollrath M et al (2013) The course of fatigue in patients with gynecologic and breast cancer. J Gynecol Oncol 24(3):280–286 · DOI
  50. Ware JE, Kosinski M (2001) Interpreting SF-36 summary health measures: a response. Qual Life Res 10(5):405–413 (discussion 415–420) · DOI

Cited by

See all 13

Metadata

Authors
Schnöder, T. M., Eberhardt, J., Koehler, M., Bierhoff, H. B., Weinert, S., Pandey, A. D., Nimmagadda, S. C., Wolleschak, D., Jöhrens, K., Fischer, T., & Heidel, F. H.
Venue
Journal of Cancer Research and Clinical Oncology
Publisher
Springer Science and Business Media LLC
Published
2017-02-23
Volume
143
Issue
5
Pages
807-820
ISSN
0171-5216
DOI
10.1007/s00432-017-2354-1
Cited by
13
References
2
Language
en
Licence
Funders
  • Deutsche Forschungsgemeinschaft (SFB 854, A20)
  • Novartis Pharma (HINC-090)
  • José Carreras Leukämie-Stiftung (SP12/04)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review